Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Jun;83(6):1930-5.
doi: 10.1172/JCI114100.

Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow

Affiliations

Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow

D E Hughes et al. J Clin Invest. 1989 Jun.

Abstract

Bisphosphonates inhibit bone resorption in vivo and in vitro by unknown mechanisms. The effect of bisphosphonates on the formation of osteoclasts from their mononuclear hematopoietic precursors was investigated using human long-term marrow cultures in which multinucleated cells form that express most of the known features of the osteoclast phenotype (e.g., bone resorption, tartrate-resistant acid phosphatase, calcitonin responsiveness, and reactivity with specific MAbs). The five bisphosphonates that were tested strongly inhibited 1,25-dihydroxyvitamin D3-stimulated formation of these cells with the same relative potencies as they inhibit bone resorption in vivo. Two representative compounds (3-amino-1-hydroxypropylidene-1,1-bisphosphonate and dichloromethylene bisphosphonate) failed to inhibit the proliferation of precursors of the osteoclast-like cells. However, these compounds decreased the proportion of mononuclear and multinucleated cells expressing an osteoclast antigen, thus suggesting a degree of specificity for cells of the osteoclast lineage. We conclude that bisphosphonates are potent inhibitors of osteoclast-like cell formation in long-term human marrow cultures, and that this may be related to their ability to inhibit bone resorption in vivo.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lancet. 1980 May 17;1(8177):1043-7 - PubMed
    1. J Immunol Methods. 1983 Dec 16;65(1-2):55-63 - PubMed
    1. J Histochem Cytochem. 1984 Feb;32(2):219-29 - PubMed
    1. Br J Cancer. 1985 May;51(5):665-9 - PubMed
    1. Clin Sci (Lond). 1985 Oct;69(4):403-11 - PubMed

Publication types